Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CareDx, Inc. stock logo
CDNA
CareDx
$71.92
-3.4%
$68.21
$15.56
▼
$90.87
$3.91B2.511.24 million shs878,537 shs
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$38.93
-3.1%
$50.96
$38.37
▼
$63.45
$3.90B1.921.92 million shs4.10 million shs
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
$14.86
-17.2%
$11.11
$1.39
▼
$24.89
$3.66B2.7314.65 million shs36.22 million shs
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
$14.00
$13.98
$0.78
▼
$25.00
$1.00B1.263.32 million shs5.45 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CareDx, Inc. stock logo
CDNA
CareDx
-3.39%-9.89%+3.93%+47.95%+350.06%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-3.14%-8.66%-21.95%-34.57%-23.26%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-17.21%+85.06%+24.04%-3.88%+877.63%
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
0.00%0.00%0.00%0.00%+47.84%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CareDx, Inc. stock logo
CDNA
CareDx
$71.92
-3.4%
$68.21
$15.56
▼
$90.87
$3.91B2.511.24 million shs878,537 shs
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$38.93
-3.1%
$50.96
$38.37
▼
$63.45
$3.90B1.921.92 million shs4.10 million shs
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
$14.86
-17.2%
$11.11
$1.39
▼
$24.89
$3.66B2.7314.65 million shs36.22 million shs
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
$14.00
$13.98
$0.78
▼
$25.00
$1.00B1.263.32 million shs5.45 million shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CareDx, Inc. stock logo
CDNA
CareDx
-3.39%-9.89%+3.93%+47.95%+350.06%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-3.14%-8.66%-21.95%-34.57%-23.26%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-17.21%+85.06%+24.04%-3.88%+877.63%
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
0.00%0.00%0.00%0.00%+47.84%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CareDx, Inc. stock logo
CDNA
CareDx
2.67
Moderate Buy$70.33-2.21% Downside
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.65
Moderate Buy$72.9387.33% Upside
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
2.33
Hold$10.00-32.71% Downside
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
2.00
Hold$14.00N/A

Current Analyst Ratings Breakdown

Latest VTYX, CDNA, CRSP, and SLS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/11/2026
CareDx, Inc. stock logo
CDNA
CareDx
Initiated CoverageOverweight$100.00
11/10/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Reiterated RatingOverweight$110.00
11/5/2026
CareDx, Inc. stock logo
CDNA
CareDx
UpgradeHold ➝ Strong-Buy
11/4/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Lower Price TargetEqual Weight$75.00 ➝ $70.00
11/4/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Boost Price TargetBuy$88.00 ➝ $90.00
11/3/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Reiterated RatingMarket Outperform
11/3/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Reiterated RatingBuy$82.00
10/30/2026
CareDx, Inc. stock logo
CDNA
CareDx
Boost Price TargetBuy$81.00 ➝ $92.00
10/30/2026
CareDx, Inc. stock logo
CDNA
CareDx
Set Price Target$99.00
10/27/2026
CareDx, Inc. stock logo
CDNA
CareDx
Boost Price TargetBuy$74.00 ➝ $81.00
10/19/2026
CareDx, Inc. stock logo
CDNA
CareDx
Boost Price TargetBuy$65.00 ➝ $80.00
(Data available from 11/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CareDx, Inc. stock logo
CDNA
CareDx
$379.80M9.95$0.01 per share11,428.75$8.90 per share8.08
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$3.51M1,075.84N/AN/A$16.99 per share2.29
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
N/AN/AN/AN/A$0.65 per shareN/A
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
N/AN/AN/AN/A$3.59 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CareDx, Inc. stock logo
CDNA
CareDx
-$21.35M$2.39112.7987.71N/A25.86%9.74%7.35%N/A
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$581.60M-$4.74N/AN/AN/A-1,812.07%-25.59%-17.89%N/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$26.86M-$0.20N/AN/AN/AN/A-31.95%-29.86%N/A
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
-$135.12M-$1.50N/AN/AN/AN/A-48.11%-43.89%N/A

Latest VTYX, CDNA, CRSP, and SLS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
-$0.05-$0.05N/A-$0.05N/AN/A
11/2/2026Q3 2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.06-$1.15-$0.09-$1.15$14.75 million$12.67 million
10/29/2026Q3 2026
CareDx, Inc. stock logo
CDNA
CareDx
$0.2548$0.70+$0.4452$0.35$121.96 million$139.36 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CareDx, Inc. stock logo
CDNA
CareDx
N/AN/AN/AN/AN/A
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/AN/AN/AN/AN/A
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
N/AN/AN/AN/AN/A
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CareDx, Inc. stock logo
CDNA
CareDx
N/A
2.31
2.25
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
0.36
16.21
16.21
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
N/A
14.92
14.92
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
N/A
17.86
17.86

Institutional Ownership

CompanyInstitutional Ownership
CareDx, Inc. stock logo
CDNA
CareDx
N/A
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
69.20%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
17.38%
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
97.88%

Insider Ownership

CompanyInsider Ownership
CareDx, Inc. stock logo
CDNA
CareDx
2.40%
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
5.20%
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
1.30%
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
14.49%
CompanyEmployeesShares OutstandingFree FloatOptionable
CareDx, Inc. stock logo
CDNA
CareDx
76552.54 million51.28 millionOptionable
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
39397.00 million91.96 millionOptionable
SELLAS Life Sciences Group, Inc. stock logo
SLS
SELLAS Life Sciences Group
13203.86 million201.21 millionOptionable
Ventyx Biosciences, Inc. stock logo
VTYX
Ventyx Biosciences
3071.76 million61.36 millionOptionable

Recent News About These Companies

UBS downgrades Ventyx Biosciences (VTYX)
Lilly confirms bid to acquire Ventyx Biosciences

New MarketBeat Followers Over Time

Media Sentiment Over Time

CareDx stock logo

CareDx NASDAQ:CDNA

$71.92 -2.52 (-3.39%)
Closing price 11/19/2026 04:00 PM Eastern
Extended Trading
$70.13 -1.79 (-2.49%)
As of 11/19/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

CRISPR Therapeutics stock logo

CRISPR Therapeutics NASDAQ:CRSP

$38.93 -1.26 (-3.14%)
Closing price 11/19/2026 04:00 PM Eastern
Extended Trading
$38.84 -0.09 (-0.23%)
As of 11/19/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

SELLAS Life Sciences Group stock logo

SELLAS Life Sciences Group NASDAQ:SLS

$14.86 -3.09 (-17.21%)
Closing price 11/19/2026 04:00 PM Eastern
Extended Trading
$14.89 +0.03 (+0.21%)
As of 11/19/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Ventyx Biosciences stock logo

Ventyx Biosciences NASDAQ:VTYX

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.